|
US459007A
(en)
|
|
1891-09-08 |
|
Porte |
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4169888A
(en)
|
1977-10-17 |
1979-10-02 |
The Upjohn Company |
Composition of matter and process
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
US4364935A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
|
JPH0684377B2
(ja)
|
1986-04-17 |
1994-10-26 |
協和醗酵工業株式会社 |
新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5053394A
(en)
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
US5084468A
(en)
|
1988-08-11 |
1992-01-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Dc-88a derivatives
|
|
JP2598116B2
(ja)
|
1988-12-28 |
1997-04-09 |
協和醗酵工業株式会社 |
新規物質ｄｃ１１３
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
JP2510335B2
(ja)
|
1989-07-03 |
1996-06-26 |
協和醗酵工業株式会社 |
Ｄｃ―８８ａ誘導体
|
|
US5187186A
(en)
|
1989-07-03 |
1993-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Pyrroloindole derivatives
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
CA2082152C
(en)
|
1990-05-07 |
1997-11-18 |
Kyriacos C. Nicolaou |
Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides
|
|
US5968509A
(en)
|
1990-10-05 |
1999-10-19 |
Btp International Limited |
Antibodies with binding affinity for the CD3 antigen
|
|
KR100240308B1
(ko)
|
1991-03-06 |
2000-01-15 |
플레믹 크리스티안 |
인간화된단클론성항체및혼성단클론성항체
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
DK0563475T3
(da)
|
1992-03-25 |
2000-09-18 |
Immunogen Inc |
Konjugater af cellebindende midler og derivater af CC-1065
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
US6329507B1
(en)
|
1992-08-21 |
2001-12-11 |
The Dow Chemical Company |
Dimer and multimer forms of single chain polypeptides
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
|
SG55079A1
(en)
|
1992-12-11 |
1998-12-21 |
Dow Chemical Co |
Multivalent single chain antibodies
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
CA2173150C
(en)
|
1993-10-01 |
2004-11-30 |
Kyoichi Sakakibara |
Novel peptide derivatives
|
|
GB9401182D0
(en)
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
|
US5641780A
(en)
|
1994-04-22 |
1997-06-24 |
Kyowa Hakko Kogyo Co., Ltd. |
Pyrrolo-indole derivatives
|
|
JPH07309761A
(ja)
|
1994-05-20 |
1995-11-28 |
Kyowa Hakko Kogyo Co Ltd |
デュオカルマイシン誘導体の安定化法
|
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5550246A
(en)
|
1994-09-07 |
1996-08-27 |
The Scripps Research Institute |
Calicheamicin mimics
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
EP0831880A4
(en)
|
1995-06-07 |
2004-12-01 |
Imclone Systems Inc |
ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
|
|
US7696338B2
(en)
|
1995-10-30 |
2010-04-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxin fusion proteins and means for expression thereof
|
|
ATE234635T1
(de)
|
1995-12-22 |
2003-04-15 |
Bristol Myers Squibb Co |
Verzweigte hydrazongruppen enthaltende kuppler
|
|
WO1997024373A1
(en)
|
1995-12-29 |
1997-07-10 |
Medvet Science Pty. Limited |
Monoclonal antibody antagonists to haemopoietic growth factors
|
|
AUPN999096A0
(en)
|
1996-05-22 |
1996-06-13 |
Northstar Biologicals Pty Ltd |
Peptides, antibodies, vaccines & uses thereof
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
DK1049787T3
(da)
|
1998-01-23 |
2005-04-04 |
Vlaams Interuniv Inst Biotech |
Antistofderivater med flere anvendelsesmuligheder
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
DK1071752T3
(da)
|
1998-04-21 |
2003-10-20 |
Micromet Ag |
CD19xCD3-specifikke polypeptider og anvendelsen deraf
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
US7074405B1
(en)
|
1998-06-22 |
2006-07-11 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US6939545B2
(en)
|
1999-04-28 |
2005-09-06 |
Genetics Institute, Llc |
Composition and method for treating inflammatory disorders
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
|
US6716410B1
(en)
|
1999-10-26 |
2004-04-06 |
The Regents Of The University Of California |
Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
|
|
RU2317999C2
(ru)
|
2000-02-25 |
2008-02-27 |
Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез |
SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
US20010035606A1
(en)
|
2000-03-28 |
2001-11-01 |
Schoen Alan H. |
Set of blocks for packing a cube
|
|
JP2003533187A
(ja)
|
2000-05-03 |
2003-11-11 |
アムジエン・インコーポレーテツド |
治療薬としてのＦｃドメインを含む修飾ペプチド
|
|
BR0110927A
(pt)
|
2000-05-19 |
2003-03-11 |
Scancell Ltd |
Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
|
|
JP2004511430A
(ja)
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
二重特異性免疫グロブリン様抗原結合蛋白および製造方法
|
|
ATE545703T1
(de)
|
2000-07-25 |
2012-03-15 |
Immunomedics Inc |
Multivalentes zielbindendes protein
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
DE10043437A1
(de)
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
|
CA2424977C
(en)
|
2000-10-06 |
2008-03-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
CN102311986B
(zh)
|
2000-10-06 |
2015-08-19 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
AU2002251913A1
(en)
|
2001-02-02 |
2002-08-19 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
JP2005500018A
(ja)
|
2001-04-02 |
2005-01-06 |
アイデック ファーマスーティカルズ コーポレイション |
ＧｎＴＩＩＩと同時発現する組換え抗体
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US7129261B2
(en)
|
2001-05-31 |
2006-10-31 |
Medarex, Inc. |
Cytotoxic agents
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
JP4298498B2
(ja)
|
2001-06-13 |
2009-07-22 |
ゲンマブ エー／エス |
上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
|
|
WO2003002144A1
(en)
|
2001-06-26 |
2003-01-09 |
Imclone Systems Incorporated |
Bispecific antibodies that bind to vegf receptors
|
|
US20030157108A1
(en)
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20080219974A1
(en)
|
2002-03-01 |
2008-09-11 |
Bernett Matthew J |
Optimized antibodies that target hm1.24
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
NZ571508A
(en)
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
|
WO2005056606A2
(en)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
WO2004043493A1
(en)
|
2002-11-14 |
2004-05-27 |
Syntarga B.V. |
Prodrugs built as multiple self-elimination-release spacers
|
|
NZ540555A
(en)
|
2002-11-15 |
2008-04-30 |
Genmab As |
Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
|
|
CN1753912B
(zh)
*
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
CR20170291A
(es)
|
2003-05-20 |
2017-07-27 |
Immunogen Inc |
Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
JP2008501621A
(ja)
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
WO2004106383A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical composition comprising a bispecific antibody for epcam
|
|
US7888134B2
(en)
|
2003-06-05 |
2011-02-15 |
Oakland University |
Immunosensors: scFv-linker design for surface immobilization
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
US20050176028A1
(en)
|
2003-10-16 |
2005-08-11 |
Robert Hofmeister |
Deimmunized binding molecules to CD3
|
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
WO2005112919A2
(en)
|
2004-05-19 |
2005-12-01 |
Medarex, Inc. |
Self-immolative linkers and drug conjugates
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
CA2569509C
(en)
|
2004-06-03 |
2014-08-12 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
|
WO2006004910A2
(en)
|
2004-06-28 |
2006-01-12 |
Transtarget Inc. |
Improved bispecific antibodies
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
AU2005282720B2
(en)
|
2004-09-02 |
2011-08-04 |
Genentech, Inc. |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
CN101103045B
(zh)
|
2004-09-24 |
2015-11-25 |
安姆根有限公司 |
修饰的Fc分子
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8066989B2
(en)
|
2004-11-30 |
2011-11-29 |
Trion Pharma Gmbh |
Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
|
|
KR20130105885A
(ko)
|
2005-01-05 |
2013-09-26 |
에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. |
상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
|
|
JP4986633B2
(ja)
|
2005-01-12 |
2012-07-25 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
|
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
JP5089582B2
(ja)
|
2005-06-07 |
2012-12-05 |
エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー |
ＴＮＦαを阻害する安定な可溶性抗体
|
|
EP1899477A4
(en)
|
2005-07-01 |
2010-01-20 |
Medimmune Inc |
INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS
|
|
DE602006020577D1
(de)
|
2005-07-01 |
2011-04-21 |
Dako Denmark As |
Monomere und polymere linker zur konjugierung von biologischen molekülen und anderen stoffen
|
|
ES2460517T3
(es)
|
2005-07-25 |
2014-05-13 |
Emergent Product Development Seattle, Llc |
Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
|
|
CA2616386A1
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals Inc. |
Single dose use of cd20-specific binding molecules
|
|
CA2617907A1
(en)
|
2005-08-05 |
2007-02-15 |
Syntarga B.V. |
Triazole-containing releasable linkers and conjugates comprising the same
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EA014025B1
(ru)
|
2005-09-12 |
2010-08-30 |
Новиммун С.А. |
Композиции антитела против cd3
|
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
KR20150139636A
(ko)
|
2005-10-12 |
2015-12-11 |
모르포시스 아게 |
인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
|
|
JP2009511067A
(ja)
|
2005-10-14 |
2009-03-19 |
メディミューン，エルエルシー |
抗体ライブラリーの細胞提示
|
|
WO2007047829A2
(en)
|
2005-10-19 |
2007-04-26 |
Laboratoires Serono S.A. |
Novel heterodimeric proteins and uses thereof
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
TW200732350A
(en)
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
EP1957541A2
(en)
|
2005-11-21 |
2008-08-20 |
Laboratoires Serono SA |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
|
RU2008129827A
(ru)
|
2005-12-21 |
2010-01-27 |
МЕДИММЬЮН, ЭлЭлСи (US) |
МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
|
|
MX357691B
(es)
|
2006-01-13 |
2018-07-19 |
The Government Of The United States As Represented By The Secretary Of The Department Of Health And |
Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
|
|
CN101415679A
(zh)
|
2006-02-02 |
2009-04-22 |
辛塔佳有限公司 |
水溶性cc-1065类似物及其缀合物
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
EP1829895A1
(en)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
|
|
GEP20135917B
(en)
|
2006-03-17 |
2013-09-10 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
|
IN2014DN10515A
(enExample)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
|
CN101548034B
(zh)
|
2006-10-02 |
2013-11-13 |
航道生物技术有限责任公司 |
多样性合成肽和多肽文库的设计和构建
|
|
PL2076535T3
(pl)
|
2006-10-16 |
2013-08-30 |
Salk Inst Biological Studies |
Antagoniści somatostatyny selektywni względem receptora (SSTR2)
|
|
US7862825B2
(en)
|
2007-02-21 |
2011-01-04 |
Mladen Vranic |
Method of controlling tight blood glucose by somatostatin receptor antagonists
|
|
EP2132312B1
(en)
|
2007-03-27 |
2016-01-27 |
Sea Lane Biotechnologies,llc. |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
EP1975178A1
(en)
|
2007-03-30 |
2008-10-01 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Transcytotic modular antibody
|
|
AU2008234019B2
(en)
|
2007-04-03 |
2014-05-29 |
Amgen Research (Munich) Gmbh |
Cross-species-specific bispecific binders
|
|
RU2769948C2
(ru)
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
KR20100021601A
(ko)
|
2007-05-14 |
2010-02-25 |
바이오겐 아이덱 엠에이 인코포레이티드 |
단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
|
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
|
EP2666787B1
(en)
|
2007-05-31 |
2022-02-09 |
Genmab A/S |
STABLE IgG4 ANTIBODIES
|
|
EP2164871A2
(en)
|
2007-06-12 |
2010-03-24 |
Wyeth a Corporation of the State of Delaware |
Anti-cd20 therapeutic compositions and methods
|
|
JP5191537B2
(ja)
*
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
|
WO2009017823A2
(en)
|
2007-08-01 |
2009-02-05 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health |
A fold-back diabody diphtheria toxin immunotoxin and methods of use
|
|
WO2009017394A1
(en)
|
2007-08-01 |
2009-02-05 |
Syntarga B.V. |
Substituted cc-1065 analogs and their conjugates
|
|
US20090130105A1
(en)
|
2007-08-28 |
2009-05-21 |
Biogen Idec Ma Inc. |
Compositions that bind multiple epitopes of igf-1r
|
|
EP2033657A1
(de)
|
2007-09-04 |
2009-03-11 |
Trion Pharma Gmbh |
Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
|
|
MX2010002683A
(es)
|
2007-09-14 |
2010-03-26 |
Amgen Inc |
Poblaciones de anticuerpos homogeneos.
|
|
DK3059246T3
(en)
|
2007-09-26 |
2018-10-01 |
Chugai Pharmaceutical Co Ltd |
Modified constant region of an antibody
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
JP5592792B2
(ja)
|
2007-09-26 |
2014-09-17 |
ユセベ ファルマ ソシエテ アノニム |
二重特異性抗体の融合体
|
|
PL2808343T3
(pl)
|
2007-12-26 |
2019-11-29 |
Xencor Inc |
Warianty Fc ze zmienionym wiązaniem do FcRn
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
WO2009106096A1
(en)
|
2008-02-27 |
2009-09-03 |
Fresenius Biotech Gmbh |
Treatment of resistant tumors with trifunctional antibodies
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
US8314213B2
(en)
|
2008-04-18 |
2012-11-20 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
|
ES2458541T5
(en)
|
2008-05-02 |
2025-08-04 |
Seagen Inc |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
|
WO2010028796A1
(en)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Trispecific hexavalent antibodies
|
|
AU2009290543B2
(en)
*
|
2008-09-12 |
2015-09-03 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
WO2010033736A1
(en)
|
2008-09-17 |
2010-03-25 |
Xencor, Inc. |
Novel compositons and methods for treating ige-mediated disorders
|
|
US20170247470A9
(en)
|
2008-09-17 |
2017-08-31 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
BRPI0919382A2
(pt)
|
2008-09-26 |
2016-01-05 |
Roche Glycart Ag |
anticorpos bi-específicos anti-egfr/anti-igf-1r
|
|
RU2547600C2
(ru)
|
2008-10-01 |
2015-04-10 |
Эмджен Рисерч (Мьюник) Гмбх |
Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
|
|
EP3106468A1
(en)
|
2008-10-01 |
2016-12-21 |
Amgen Research (Munich) GmbH |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
|
AU2009299793B2
(en)
|
2008-10-01 |
2016-03-10 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
EA032828B1
(ru)
|
2008-10-10 |
2019-07-31 |
Аптево Рисёрч Энд Девелопмент Ллс |
Иммунотерапевтические средства против комплекса tcr
|
|
CA2742568C
(en)
|
2008-11-03 |
2017-09-26 |
Syntarga B.V. |
Novel cc-1065 analogs and their conjugates
|
|
WO2010085682A2
(en)
|
2009-01-23 |
2010-07-29 |
Biogen Idec Ma Inc. |
Stabilized fc polypeptides with reduced effector function and methods of use
|
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
|
CN102369214B
(zh)
|
2009-04-07 |
2019-04-12 |
罗氏格黎卡特股份公司 |
三价、双特异性抗体
|
|
KR20110126748A
(ko)
|
2009-04-07 |
2011-11-23 |
로슈 글리카트 아게 |
이중특이적 항-ｅｒｂｂ-1/항-ｃ-ｍｅｔ 항체
|
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
EP2241576A1
(en)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
|
|
EP2435473B1
(en)
|
2009-05-27 |
2013-10-02 |
F.Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
|
US8969082B2
(en)
|
2009-06-26 |
2015-03-03 |
Sea Lane Biotechnologies, Llc |
Expression of surrogate light chains
|
|
KR101747103B1
(ko)
|
2009-06-26 |
2017-06-14 |
리제너론 파마슈티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
|
AU2010270844A1
(en)
|
2009-07-08 |
2011-12-22 |
Amgen Inc. |
Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
DE102009045006A1
(de)
|
2009-09-25 |
2011-04-14 |
Technische Universität Dresden |
Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
|
|
NZ598732A
(en)
|
2009-10-27 |
2014-09-26 |
Amgen Res Munich Gmbh |
Dosage regimen for administering a cd19xcd3 bispecific antibody
|
|
AU2010321720B2
(en)
|
2009-11-23 |
2017-03-02 |
Amgen Inc. |
Monomeric antibody Fc
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
PL2506871T3
(pl)
|
2009-11-30 |
2017-03-31 |
Janssen Biotech, Inc |
Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi
|
|
RU2606264C2
(ru)
|
2009-12-25 |
2017-01-10 |
Чугаи Сеияку Кабушики Каиша |
Способ полипептидной модификации для очистки полипептидных мультимеров
|
|
SG181952A1
(en)
|
2009-12-29 |
2012-07-30 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
|
US20110189178A1
(en)
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
|
MX341925B
(es)
|
2010-03-29 |
2016-09-07 |
Zymeworks Inc |
Anticuerpos con funcion efectora suprimida o mejorada.
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
PL2560993T3
(pl)
|
2010-04-20 |
2024-11-04 |
Genmab A/S |
Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
|
|
US9637557B2
(en)
|
2010-04-23 |
2017-05-02 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
EP3613774A1
(en)
|
2010-06-09 |
2020-02-26 |
Genmab A/S |
Antibodies against human cd38
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
SMT201700250T1
(it)
|
2010-11-10 |
2017-07-18 |
Amgen Res Munich Gmbh |
Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
|
|
JP2014502262A
(ja)
|
2010-11-12 |
2014-01-30 |
ザ ロックフェラー ユニバーシティ |
Ｈｉｖ治療用の融合タンパク質
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
US9266938B2
(en)
|
2011-02-10 |
2016-02-23 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
EP2686682A4
(en)
|
2011-03-11 |
2015-03-11 |
Amgen Inc |
METHOD FOR CORRELATED MUTATION ANALYSIS TO IMPROVE THERAPEUTIC ANTIBODIES
|
|
ES2668895T3
(es)
|
2011-03-16 |
2018-05-23 |
Amgen Inc. |
Variantes de Fc
|
|
US9683052B2
(en)
|
2011-03-25 |
2017-06-20 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
TWI588156B
(zh)
|
2011-03-28 |
2017-06-21 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
CA2832360C
(en)
|
2011-04-28 |
2022-05-03 |
Amgen Research (Munich) Gmbh |
Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
CN107827985A
(zh)
|
2011-05-21 |
2018-03-23 |
宏观基因有限公司 |
能够与人和非人cd3结合的cd3结合分子
|
|
WO2012162277A1
(en)
|
2011-05-25 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES
|
|
EP2729488A4
(en)
|
2011-07-06 |
2015-01-14 |
Medimmune Llc |
PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
|
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
RU2624049C2
(ru)
|
2011-08-04 |
2017-06-30 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
|
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
|
ES2682254T3
(es)
|
2011-08-18 |
2018-09-19 |
Affinity Biosciences Pty Ltd |
Polipéptidos solubles
|
|
PH12013502531A1
(en)
|
2011-08-23 |
2014-01-20 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
MX2014002289A
(es)
|
2011-08-26 |
2015-03-20 |
Merrimack Pharmaceuticals Inc |
Anticuerpos fc especificos en tandem.
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2851534C
(en)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
A method for purifying antibodies
|
|
CN109608543A
(zh)
|
2011-10-20 |
2019-04-12 |
艾斯巴技术-诺华有限责任公司 |
稳定的多抗原结合抗体
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
EP2787078B1
(en)
|
2011-10-31 |
2019-05-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
EP2776061B1
(en)
|
2011-11-07 |
2019-08-14 |
MedImmune, LLC |
Multispecific and multivalent binding proteins and uses thereof
|
|
EP2793940B1
(en)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
|
TW202500756A
(zh)
|
2012-02-24 |
2025-01-01 |
日商中外製藥股份有限公司 |
經FcγRIIB促進抗原消失之抗原結合分子
|
|
DK2838917T3
(da)
|
2012-04-20 |
2019-08-26 |
Merus Nv |
Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
|
|
MY174248A
(en)
|
2012-04-30 |
2020-04-01 |
Biocon Ltd |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
EP4053162A1
(en)
|
2012-05-18 |
2022-09-07 |
Aptevo Research and Development LLC |
Bispecific scfv immunofusion (bif) binding to cd123 and cd3
|
|
EP3892638A1
(en)
|
2012-05-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
US20140154253A1
(en)
|
2012-07-13 |
2014-06-05 |
Zymeworks Inc. |
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
|
|
AU2013293092A1
(en)
|
2012-07-23 |
2015-02-26 |
Zymeworks Inc. |
Immunoglobulin constructs comprising selective pairing of the light and heavy chains
|
|
KR101744038B1
(ko)
|
2012-07-30 |
2017-06-07 |
후지필름 가부시키가이샤 |
감광성 수지 조성물, 경화막의 제조 방법, 경화막, 유기 ｅｌ 표시 장치 및 액정 표시 장치
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
|
US20140161790A1
(en)
|
2012-11-19 |
2014-06-12 |
Xencor, Inc. |
Engineered immunoglobulins with extended in vivo half-life
|
|
CN112079929A
(zh)
|
2012-11-21 |
2020-12-15 |
武汉友芝友生物制药有限公司 |
双特异性抗体
|
|
EP2927321B1
(en)
|
2012-11-27 |
2021-02-17 |
Ajou University Industry-Academic Cooperation Foundation |
Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
EP2934577A1
(en)
|
2012-12-19 |
2015-10-28 |
Adimab, LLC |
Multivalent antibody analogs, and methods of their preparation and use
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
AU2014249243C1
(en)
|
2013-03-13 |
2019-08-08 |
Imaginab, Inc. |
Antigen binding constructs to CD8
|
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014209804A1
(en)
*
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
CN105612175B
(zh)
|
2013-08-08 |
2023-05-09 |
赛腾制药 |
基于IL-15和IL-15Rαsushi结构域的调节因子
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP3066133A1
(en)
|
2013-11-04 |
2016-09-14 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
MX2016007885A
(es)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
KR102225489B1
(ko)
|
2013-12-17 |
2021-03-10 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
NZ720353A
(en)
*
|
2013-12-30 |
2019-12-20 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
RU2689717C2
(ru)
|
2014-01-08 |
2019-05-28 |
Шанхай Хэнжуй Фармасьютикал Ко., Лтд. |
Гетеродимерный белок il-15 и его применения
|
|
ES2716685T3
(es)
*
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
KR102497443B1
(ko)
*
|
2014-03-28 |
2023-02-08 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
RU2577226C2
(ru)
|
2014-04-10 |
2016-03-10 |
Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
|
|
JP7348708B2
(ja)
|
2014-04-30 |
2023-09-21 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
組み合わせワクチン装置および癌細胞を殺滅する方法
|
|
TWI742423B
(zh)
|
2014-05-29 |
2021-10-11 |
美商宏觀基因股份有限公司 |
特異性結合多種癌症抗原的三特異性結合分子和其使用方法
|
|
CA2956178A1
(en)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US9982053B2
(en)
*
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
EP3191187B1
(en)
|
2014-09-09 |
2021-07-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-cd38 antibodies
|
|
MA40894A
(fr)
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
BR112017011166A2
(pt)
*
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
RS63384B1
(sr)
|
2015-01-08 |
2022-08-31 |
BioNTech SE |
Agonistička sredstva za vezivanje tnf receptora
|
|
US20180318417A1
(en)
|
2015-01-14 |
2018-11-08 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
MA41279A
(fr)
|
2015-05-08 |
2021-04-28 |
Xencor Inc |
Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
|
|
PE20181090A1
(es)
|
2015-06-24 |
2018-07-09 |
Janssen Biotech Inc |
Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
US20180305465A1
(en)
|
2015-11-25 |
2018-10-25 |
Amgen Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
MA44146B1
(fr)
|
2015-12-22 |
2023-10-31 |
Regeneron Pharma |
Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
WO2017210443A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd123 and cd3
|
|
EP3464370A1
(en)
|
2016-06-01 |
2019-04-10 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
US20200255524A1
(en)
|
2016-06-07 |
2020-08-13 |
Macrogenics, Inc. |
Combination therapy
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
|
US20190309092A1
(en)
|
2016-07-21 |
2019-10-10 |
Development Center For Biotechnology |
Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
|
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
|
IL303187A
(en)
|
2016-08-29 |
2023-07-01 |
Akamis Bio Ltd |
Adenovirus with bispecific T cell activator
|
|
US10793632B2
(en)
*
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
PE20240950A1
(es)
*
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
KR102617264B1
(ko)
|
2016-10-19 |
2023-12-29 |
인벤라 인코포레이티드 |
항체 구조물
|
|
US20210061911A1
(en)
|
2017-09-07 |
2021-03-04 |
Macrogenics, Inc. |
Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
|
|
KR20200085828A
(ko)
*
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
US10981992B2
(en)
*
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20210003814A
(ko)
*
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
EP3781597A1
(en)
*
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
AU2020232605A1
(en)
*
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
WO2021026387A2
(en)
|
2019-08-06 |
2021-02-11 |
Xencor, Inc. |
HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
|
|
JP7773528B2
(ja)
*
|
2020-08-19 |
2025-11-19 |
ゼンコア インコーポレイテッド |
抗ｃｄ２８組成物
|
|
WO2023196905A1
(en)
*
|
2022-04-07 |
2023-10-12 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|